F-18 ML-104 tau PET imaging in mild cognitive impairment

Jasim Jaleel1, Madhavi Tripathi1, Vivek Baghel1

  • 1Department of Nuclear Medicine.

Abstract

Insights

This study shows increased tau deposition in the brains of patients with amnestic mild cognitive impairment (aMCI) compared to healthy individuals. This finding provides in vivo evidence of tau pathology in aMCI, a condition often preceding Alzheimer's disease.

Area of Science:

  • Neuroimaging
  • Neurology
  • Molecular Imaging

Background:

  • Amnestic mild cognitive impairment (aMCI) is a transitional stage between normal aging and Alzheimer's disease (AD).
  • Understanding the in vivo pathological changes in aMCI is crucial for early diagnosis and intervention.

Purpose of the Study:

  • To evaluate tau distribution patterns in patients with aMCI using the PET radiotracer F-18 ML-104.
  • To compare tau deposition in aMCI patients with normal controls and early AD patients.

Main Methods:

  • Thirty aMCI patients underwent F-18 fluorodeoxyglucose and F-18 ML-104 tau PET scans.
  • Standardized uptake value ratios (SUVRs) in cortical gray matter regions were analyzed.
  • aMCI SUVRs were compared to those of normal controls and previously studied early AD patients.

Main Results:

  • aMCI patients showed significantly higher F-18 ML-104 retention in medial temporal, precuneus, and posterior cingulate cortices compared to normal controls.
  • aMCI patients exhibited lower F-18 ML-104 retention in these regions compared to early AD patients.
  • Negative correlations were observed between glucose metabolism (F-18 FDG uptake) and tau retention (F-18 ML-104) in the precuneus and posterior cingulate cortices in aMCI.

Conclusions:

  • Significant cortical tau deposition was demonstrated in aMCI patients compared to normal controls.
  • This study provides in vivo evidence of tau pathology in aMCI.
  • These findings highlight aMCI as a stage with high probability of conversion to AD due to underlying tau pathology.